Literature DB >> 18216870

Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma.

H Paripati, A K Stewart, S Cabou, A Dueck, V J Zepeda, N Pirooz, C Ehlenbeck, C Reeder, J Slack, J F Leis, J Boesiger, A S Torloni, R Fonseca, P L Bergsagel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18216870     DOI： 10.1038/sj.leu.2405100

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  29 in total

1.  Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.

Authors:  Lauren Veltri; Aaron Cumpston; Alexandra Shillingburg; Sijin Wen; Jin Luo; Sonia Leadmon; Kathy Watkins; Michael Craig; Mehdi Hamadani; Abraham S Kanate
Journal:  Cytotherapy       Date:  2015-10-21       Impact factor: 5.414

2.  Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study.

Authors:  S Afifi; N G Adel; S Devlin; E Duck; J Vanak; H Landau; D J Chung; N Lendvai; A Lesokhin; N Korde; L Reich; O Landgren; S Giralt; H Hassoun
Journal:  Bone Marrow Transplant       Date:  2016-01-04       Impact factor: 5.483

Review 3.  Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.

Authors:  M Mohty; K Hübel; N Kröger; M Aljurf; J Apperley; G W Basak; A Bazarbachi; K Douglas; I Gabriel; L Garderet; C Geraldes; O Jaksic; M W Kattan; Z Koristek; F Lanza; R M Lemoli; L Mendeleeva; G Mikala; N Mikhailova; A Nagler; H C Schouten; D Selleslag; S Suciu; A Sureda; N Worel; P Wuchter; C Chabannon; R F Duarte
Journal:  Bone Marrow Transplant       Date:  2014-03-31       Impact factor: 5.483

Review 4.  How best to use new therapies in multiple myeloma.

Authors:  David Dingli; S Vincent Rajkumar
Journal:  Blood Rev       Date:  2010-04-01       Impact factor: 8.250

5.  Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma.

Authors:  Susan Bal; Heather J Landau; Gunjan L Shah; Michael Scordo; Parastoo Dahi; Oscar B Lahoud; Hani Hassoun; Malin Hultcrantz; Neha Korde; Nikoletta Lendvai; Alexander M Lesokhin; Sham Mailankody; Urvi A Shah; Eric Smith; Sean M Devlin; Scott Avecilla; Ahmet Dogan; Mikhail Roshal; Ola Landgren; Sergio A Giralt; David J Chung
Journal:  Biol Blood Marrow Transplant       Date:  2020-05-19       Impact factor: 5.742

6.  Multiple myeloma: biology, standard therapy, and transplant therapy.

Authors:  Morie A Gertz; Irene Ghobrial; Jean Luc-Harousseau
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

7.  Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma.

Authors:  M A Gertz; S K Kumar; M Q Lacy; A Dispenzieri; S R Hayman; F K Buadi; D Dingli; D A Gastineau; J L Winters; M R Litzow
Journal:  Bone Marrow Transplant       Date:  2008-11-10       Impact factor: 5.483

8.  Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.

Authors:  Uday Popat; Rima Saliba; Rupinderjit Thandi; Chitra Hosing; Muzaffar Qazilbash; Paolo Anderlini; Elizabeth Shpall; John McMannis; Martin Körbling; Amin Alousi; Borje Andersson; Yago Nieto; Partow Kebriaei; Issa Khouri; Marcos de Lima; Donna Weber; Sheeba Thomas; Michael Wang; Roy Jones; Richard Champlin; Sergio Giralt
Journal:  Biol Blood Marrow Transplant       Date:  2009-04-08       Impact factor: 5.742

9.  Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.

Authors:  Tomer Mark; Jessica Stern; Jessica R Furst; David Jayabalan; Faiza Zafar; April LaRow; Roger N Pearse; John Harpel; Tsiporah Shore; Michael W Schuster; John P Leonard; Paul J Christos; Morton Coleman; Ruben Niesvizky
Journal:  Biol Blood Marrow Transplant       Date:  2008-07       Impact factor: 5.742

10.  Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.

Authors:  C B Reeder; D E Reece; V Kukreti; C Chen; S Trudel; J Hentz; B Noble; N A Pirooz; J E Spong; J G Piza; V H J Zepeda; J R Mikhael; J F Leis; P L Bergsagel; R Fonseca; A K Stewart
Journal:  Leukemia       Date:  2009-02-19       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.